Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Thierry Abribat
|
| gptkbp:developedBy |
peptide therapeutics
|
| gptkbp:focusesOn |
rare endocrine diseases
|
| gptkbp:formerName |
Alizé Pharma 3
|
| gptkbp:foundedIn |
2014
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
gptkb:Lyon,_France |
| https://www.w3.org/2000/01/rdf-schema#label |
Amolyt Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProductCandidate |
eneboparatide (AZP-3601)
|
| gptkbp:leadProductIndication |
gptkb:hypoparathyroidism
|
| gptkbp:operatesIn |
gptkb:France
gptkb:United_States |
| gptkbp:website |
https://www.amolytpharma.com/
|
| gptkbp:bfsParent |
gptkb:Novo_Holdings
|
| gptkbp:bfsLayer |
7
|